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Statement of translational relevance 41 
Endocrine resistance is a challenge for patients with estrogen receptor (ER) positive breast cancer. 42 
Fulvestrant, a selective estrogen receptor degrader (SERD), is a standard of care medication for 43 
advanced ER+/HER2− metastatic breast cancer, but its intramuscular administration restricts the 44 
maximum feasible dose. Orally bioavailable SERDs may achieve greater clinical anti-ER activity than 45 
fulvestrant, which may translate into improved clinical outcomes. 46 
This Phase 1 study reports safety, tolerability, pharmacokinetics, and preliminary antitumor activity 47 
of the oral SERD AZD9496, which shows prolonged disease stabilization in some heavily pre-treated 48 
patients with ER+/HER2− metastatic breast cancer, including those previously treated with 49 
fulvestrant.  These results support the further clinical development of AZD9496. 50 
Oral SERDs could be the next generation of endocrine therapy and are a priority for clinical 51 
investigation. 52 
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Abstract 53 
Purpose: AZD9496 is an oral non-steroidal, small-molecule inhibitor of estrogen receptor alpha 54 
(ERα), and a potent and selective antagonist and degrader of ERα. This first in human Phase 1 study 55 
determined the safety and tolerability of ascending doses of oral AZD9496 in women with estrogen 56 
receptor (ER)+/HER2– advanced breast cancer, characterized its pharmacokinetic (PK) profile, and 57 
made preliminary assessment of antitumor activity. 58 
Experimental design: Forty-five patients received AZD9496 (20 mg once daily to 600 mg twice daily) 59 
in a dose-escalation, dose- expansion ‘rolling 6’ design. Safety, tolerability, and PK activity in each 60 
cohort was reviewed before escalating to the next dose. PK was determined by mass spectrometry. 61 
Adverse events (AEs) were graded according to the Common Terminology Criteria for Adverse 62 
Events (CTCAE) v4.0. Objective tumor response was evaluated by Response Evaluation Criteria in 63 
Solid Tumors (RECIST) v1.1. 64 
Results: Most common causally related AEs were diarrhea (35.6%), fatigue (31.1%), and nausea 65 
(22.2%), and seven patients had grade ≥3 AEs. Three patients experienced a dose-limiting toxicity 66 
(DLT): one each at 150 mg BID (abnormal hepatic function), 400 mg BID (diarrhea and elevated liver 67 
function tests) and 600 mg BID (diarrhea), and all were reversible. The maximum tolerated dose was 68 
not reached. Partial response was confirmed in one patient, who also had decreased tumor marker 69 
Ca15.3. Four patients had stable disease at 12 months’ follow up. 70 
Conclusions: AZD9496 is well tolerated with an acceptable safety profile, showing evidence of 71 
prolonged disease stabilization in heavily pre-treated patients with ER+/HER2– advanced breast 72 
cancer. 73 
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[Body text] 74 
Introduction 75 
Approximately 70% of breast cancers are estrogen receptor (ER) positive, and inhibiting estrogen 76 
receptor (ER) signaling is a mainstay of treatment (1). Three classes of endocrine agents are used: 77 
aromatase inhibitors, selective estrogen receptor modulators (SERMs), and selective estrogen 78 
receptor degraders (SERDs); each with unique modes of action. Aromatase inhibitors prevent the 79 
conversion of androgens to estrogens (2), SERMs bind to the ER and act as mixed 80 
antagonists/agonists (3), and SERDs bind to, antagonize, and degrade the ER (4). 81 
Current endocrine therapies can be effective, but many patients develop primary or secondary 82 
resistance, ultimately leading to disease progression and death. Therefore, drug resistance is a major 83 
clinical challenge (1). Only around 30% of patients with metastatic breast cancer achieve objective 84 
tumor regression with initial endocrine treatment, and another 20% experience prolonged stable 85 
disease (5). Resistance mechanisms include deregulation of the ER pathway itself, alterations in cell 86 
cycle and cell survival signaling molecules, development of escape pathways, and acquisition of 87 
activating mutations in the ER gene (ESR1) that allow tumors to survive and proliferate without 88 
depending on estrogen (5). Although the benefit of SERMs and aromatase inhibitors declines after 89 
resistance develops, it is well known that the ER itself remains involved in the pathogenesis and 90 
progression of advanced disease, and therefore remains an important therapeutic target (6-9). 91 
Fulvestrant is the only SERD approved for treating advanced ER+/HER2− metastatic breast cancer, 92 
and is effective in both endocrine treatment-naïve patients, and in those whose disease has 93 
progressed whilst on other endocrine therapies (10-12). Indeed, although ESR1 mutations appear to 94 
predict resistance to aromatase inhibitor therapy, such mutations do not appear to influence 95 
outcomes in patients treated with fulvestrant (13). Fulvestrant is a standard of care medication for 96 
advanced ER+/HER2− metastatic breast cancer, but has some limitations: intramuscular injection 97 
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restricts the maximum feasible dose (MFD) to 500 mg once a month, and steady state plasma 98 
concentrations are not reached until 3 to 6 months after first administration (14,15). Furthermore, a 99 
recent study indicated that the MFD of fulvestrant may be insufficient to fully reduce ER in some 100 
patients, and this can be associated with earlier disease progression (16). These limitations suggest 101 
that an agent inducing even greater combined ER targeting and degradation than fulvestrant would 102 
be highly desirable (15). 103 
An orally bioavailable SERD may overcome some of the limitations associated with intramuscular 104 
fulvestrant, help patients avoid painful injections, and ease delivery in pressured healthcare systems. 105 
An oral SERD may reach steady state more quickly, and might be given at higher relative doses; 106 
enhancing target engagement, and potentially deliver superior clinical benefits to patients with ER+ 107 
breast cancer. 108 
AZD9496 is a new oral, non-steroidal, small-molecule inhibitor of ERα, and is a potent and selective 109 
antagonist and degrader of ERα in ER+ breast cancer models (IC50s from different assays are ≤1 nM) 110 
(17). Data show that AZD9496 significantly inhibits tumor growth and decreases expression of 111 
progesterone receptor (PR) protein in estrogen-dependent MCF-7 xenograft models and in 112 
patient-derived ESR1 mutant in vivo models (17). AZD9496 also caused tumor regression and 113 
downregulated ERα expression in the HCC1428 cell long-term estrogen-deprived breast cancer 114 
model of resistance to aromatase inhibitor treatment (17). 115 
This first in human study investigated the safety and tolerability of ascending doses of AZD9496 116 
when given orally to women with advanced ER+/HER2− metastatic breast cancer, and characterized 117 
its pharmacokinetic (PK) profile. 118 
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Patients and methods 119 
Study design and objectives 120 
This study (NCT02248090) was a multicenter, global, Phase 1, open-label, first in human study that 121 
comprised two parts: dose escalation and dose expansion. This study was carried out in accordance 122 
with the principles of the International Conference on Harmonization guidelines for Good Clinical 123 
Practice, the Declaration of Helsinki, and all applicable laws. 124 
The primary objective was to investigate the safety and tolerability of ascending doses of oral 125 
AZD9496 in patients with metastatic or locoregionally recurrent ER+/HER2− advanced breast cancer. 126 
Secondary objectives were to characterize the PK of AZD9496 and its metabolites after a single oral 127 
dose and at steady state after multiple doses, and to obtain a preliminary assessment of anti-tumor 128 
efficacy. Exploratory analyses included investigating potential determinants of response or 129 
resistance to AZD9496 in plasma (such as ESR1 mutation status in circulating tumor DNA), and 130 
pharmacodynamic biomarker changes in tumor tissue and circulating tumor cells will be reported 131 
separately (manuscript in preparation).  132 
Patient selection and screening 133 
Patients were recruited from hospitals in the US, UK, and Korea. The protocol was approved by the 134 
respective regulatory authorities and the research ethics committee of each participating site, and 135 
was subject to Ethics Committee and Institutional Review Board approvals. All patients provided 136 
their written informed consent at study enrollment. Patients were screened within 28 days prior to 137 
study admission to gather demographic data and standard medical and surgical history. 138 
Patient eligibility 139 
Key inclusion criteria included: female patients of any menopausal status, aged at least 18 years, and 140 
with a diagnosis of ER+/HER2− adenocarcinoma of the breast, metastatic or locoregionally recurrent, 141 
and not amenable to treatment with curative intent. Pre- or peri-menopausal women must have 142 
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started luteinizing hormone-releasing hormone (LHRH) agonist treatment at least 4 weeks before 143 
study treatment, and must have continued this treatment throughout the study. Disease must have 144 
progressed after at least 6 months of endocrine therapy for ER+ breast cancer. (Before protocol 145 
amendment 21 August 2015, patients must have spent ≥6 months on a line of endocrine therapy in 146 
the advanced setting). Radiological or objective evidence of progression on or after the last systemic 147 
therapy was needed before starting study treatment. 148 
Key exclusion criteria included receipt of more than two lines of chemotherapy for advanced 149 
disease, or systemic anti-cancer therapy within 14 days of the first dose of study treatment. 150 
Radiotherapy for palliation was permitted if received more than 1 week before the first dose of 151 
study treatment. Patients were excluded if they were receiving any medications known to induce or 152 
inhibit CYP3A4/5 or CYP2C8, or had life-threatening visceral, central nervous system or pulmonary 153 
lymphangitic metastases, inadequate bone marrow reserve or organ function, unexplained 154 
symptomatic endometrial disorders, uncontrolled symptomatic thyroid dysfunction, or an Eastern 155 
Cooperative Oncology Group (ECOG) performance status of ≥2. 156 
Dose escalation and dose expansion 157 
A ‘rolling 6’ design was employed, in which each cohort of at least three and up to six patients 158 
received AZD9496 at an escalating dose (18). Dosing began at 20 mg once-daily (QD). Patients were 159 
dosed in cycles: Cycles 1 to 6 each were 4 weeks long, and further cycles each were 6 weeks long. 160 
Dose-limiting toxicities (DLTs) were assessed for the first 28 days of treatment (Cycle 1), and the 161 
dose was escalated in the next cohort if no DLTs were observed in the previous cohort. If two or 162 
more patients in any cohort experienced a DLT, the dose was considered non-tolerated. If only one 163 
patient experienced a DLT, the cohort was expanded to include six evaluable patients, and if no 164 
further DLTs occurred, dose escalation could continue. Dose interruptions and reductions were 165 
permitted if patients experienced adverse events (AEs). Dose escalations were planned to continue 166 
until the maximum tolerated dose (MTD; the last dose below the non-tolerated dose) or MFD (a 167 
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reasonable number of acceptably sized tablets given, or evidence of saturation of absorption 168 
observed) was reached. Patients were dosed until confirmed disease progression, or unacceptable 169 
toxicity. 170 
 At selected doses, escalation cohorts were expanded to include six evaluable 171 
patients in order to further investigate safety, tolerability, PK, and biological 172 
activity of AZD9496.Safety and tolerability assessments 173 
Safety was assessed in terms of AEs (including treatment emergent adverse events [TEAEs; any 174 
event not present prior to receipt of first dose of study drug, or a worsening of an existing event], 175 
serious adverse events [SAEs], causally related AEs [any event deemed related to the study drug in 176 
the investigator’s opinion], AEs leading to discontinuation, and AEs leading to death), laboratory 177 
data, vital signs, electrocardiogram changes, and ECOG assessment. AE severity was graded 178 
according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 4. An 179 
independent Safety Review Committee reviewed the safety, tolerability, and preliminary PK data (if 180 
available) from patients in each escalation cohort before escalating to the next dose. 181 
Pharmacokinetic assessments 182 
Plasma PK parameters (including AUC, maximum plasma concentration [Cmax], and time to maximum 183 
plasma concentration [tmax]) were determined for AZD9496 and its metabolites M3 and M5 (30- and 184 
3-fold lower potency than parent, respectively, and both formed by oxidation of the parent) after a 185 
single dose, and at steady state after multiple dosing (i.e. 13 days of dosing in the dose escalation 186 
cohorts and 11 days in the dose expansion cohort). AZD9496 concentration was also determined in 187 
urine for patients in the dose escalation cohorts only. 4β-hydroxy-cholesterol:cholesterol ratios were 188 
determined as a marker of hepatic CYP3A4 induction potential by AZD9496. 189 
AZD9496 and metabolites were determined in plasma using a validated liquid chromatography-190 
tandem mass spectrometry (LC-MS/MS) method. The validated range was 1.00 to 5,000 ng/mL for 191 
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AZD9496, 1.00 to 2,000 ng/mL for M3 and 0.1 to 200 ng/mL for M5. AZD9496 concentrations were 192 
also determined in urine using a validated LC-MS/MS method with a validated range of 50.0 to 193 
50,000 ng/mL. For patients in the dose escalation cohorts, in Cycle 1 venous blood samples were 194 
taken pre-dose and at regular intervals on Day 1 (over 24 h) and Day 15 (over 10 h), and pre-dose on 195 
Days 2 and 16. In Cycles 2–4, samples were taken pre-dose on Day 1. For patients in the dose 196 
expansion cohorts, in Cycle 1 blood samples were taken on Day 1 (over 72 h) and Day 15 (over 10 h), 197 
and pre-dose on Day 8. In Cycles 2–4, samples were taken pre-dose on Day 1. For patients 198 
participating in PK profiling (those in the dose expansion cohort), two additional blood samples were 199 
taken pre-dose on Days 1 and 15 of Cycle 1, and Day 1 of Cycles 2–4, to determine 4β-hydroxy-200 
cholesterol:cholesterol ratios. Urine samples were collected pre-dose, and 0 to 4, 4 to 8, 8 to 10, and 201 
10 to 24 hours post-dose on Days 1 and 15 (Cycle 1 only) from patients in the dose escalation 202 
cohorts. 203 
Anti-tumor efficacy assessment 204 
Objective tumor response assessment was based on the Response Evaluation Criteria in Solid 205 
Tumors (RECIST) 1.1 guidelines for response (19). Computed tomography/magnetic resonance 206 
imaging (CT/MRI) was performed of the chest, abdomen, and pelvis (and any other sites at which 207 
new disease was suspected) of all patients at baseline (within 28 days of study start), at 8, 16, and 208 
24 weeks after the start of treatment, and every 12 weeks thereafter until objective disease 209 
progression was confirmed. Patients underwent a bone scan or skeletal survey at baseline, and at 210 
follow-up visits if clinically indicated. 211 
Data derivation and analysis 212 
The number of patients was chosen based on the desire to obtain adequate data while exposing as 213 
few patients as possible to the investigational product and procedures. The safety analysis set was 214 
all patients who received at least one dose of AZD9496. The PK analysis set was all patients who 215 
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received at least one dose of AZD9496, and who have at least one measured concentration of 216 
AZD9496 at a scheduled post-dose PK time point. 217 
PK parameters were derived by standard non-compartmental methods using Phoenix™ WinNonlin® 218 
(Certara), Version 6.4. No formal statistical analysis was done for this study; data were summarized 219 
using standard summary statistics (SAS Version 9.2). 220 
Results 221 
The study commenced in October 2014, and recruitment was completed on 26 February 2016, 222 
ahead of the final data cut-off on 31 January 2017. Forty-five patients were enrolled: all met the 223 
inclusion criteria and received AZD9496 at various doses (from 20 mg QD to 600 mg twice daily 224 
[BID]; Figure S1). Patients were allocated to cohorts containing between four and six patients, and 225 
each cohort received AZD9496 at an escalating dose. Six further patients were selected for an 226 
expansion cohort after the 400 mg BID dose escalation, and received AZD9496 at 250 mg BID at the 227 
same time as the 600 mg BID cohort. 228 
Baseline characteristics 229 
Baseline patient demographics are shown in Table 1. Patients were mostly white (n = 31; 68.9%) with 230 
a median age of 62 years (range 41 to 83 years). All patients had metastatic disease on study entry. 231 
Most patients had measurable disease (n = 39; 86.7%) and many had visceral disease (n = 36; 80.0%). 232 
Twenty-five patients (55.6%) had received prior treatment with fulvestrant before enrolling in the 233 
study. Of these, ten received fulvestrant as the immediate therapy prior to enrollment; five as a 234 
monotherapy, and five as part of combination treatment. 235 
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Safety and tolerability 236 
Forty-four patients (97.8%) experienced at least one AE, and most were CTCAE grade 1 or 2. The 237 
most common AEs of any grade were fatigue (n = 19; 42.2%), nausea (n = 18; 40.0%), and diarrhea (n 238 
= 17; 37.8%). 239 
Forty patients (88.9%) experienced AEs that were considered by the investigator, using his/her 240 
clinical judgment, to be related to the study drug. The most common causally related AEs of any 241 
grade were diarrhea (n = 16; 35.6%), fatigue (n = 14; 31.1%), nausea (n = 10; 22.2%), and upper 242 
abdominal pain (n = 6; 13.3%), grading of these AEs are shown in Table 2. Causally related SAEs 243 
occurred in two patients (4.4%; diarrhea, abnormal hepatic function), and causally related AEs of 244 
CTCAE grade ≥3 or higher occurred in seven patients (15.6%). These were diarrhea (n = 3; 6.7%), 245 
increased ALT (n = 2; 4.4%), and fatigue, vomiting, and increased AST (each n = 1; 2.2%).  246 
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Table 1. Baseline characteristics of study population 247 
 
 20 mg QD 
(n = 4) 
40 mg 
BID 
(n = 6) 
80 mg 
BID 
(n = 5) 
150 mg 
BID 




(n = 12) 
400 mg 
BID 
(n = 6) 
600 mg 
BID 
(n = 6) 
Total 
(n = 45) 


















Race, n (%) 
White 3 (75.0) 4 (66.7) 3 (60.0) 5 (83.3) 9 (75.0) 4 (66.7) 3 (50.0) 31 (68.9) 
Black or African 
American 
1 (25.0) 0 0 0 1 (8.3) 0 0 2 (4.4) 
Asian 0 2 (33.3) 2 (40.0) 1 (16.7) 2 (16.7) 2 (33.3) 3 (50.0) 12 (26.7) 
Post-menopausal, n (%) 4 (100.0) 6 (100.0) 3 (60.0) 5 (83.3) 11 (91.7) 4 (66.7) 5 (83.3) 38 (84.4) 
ECOG category 0, n (%) 2 (50.0) 4 (66.7) 3 (60.0) 2 (33.3) 3 (25.0) 2 (33.3) 3 (50.0) 19 (42.2) 
Measurable disease,  
n (%) 
4 (100.0) 6 (100.0) 5 (100.0) 6 (100.0) 8 (66.7) 5 (83.3) 5 (83.3) 39 (86.7) 
Visceral diseaseb, n (%) 4 (100.0) 5 (83.3) 4 (80.0) 6 (100.0) 8 (66.7) 4 (66.7) 5 (83.3) 36 (80.0) 
Number of prior chemotherapy regimens, median (range) 
(Neo) adjuvant 
setting 
0 (0–1) 0 (0–1) 0 (0–1) 1 (0–1) 1 (0–1) 1 (0–1) 1 (0–1) 1 (0-1) 
Advanced setting 0.5 (0–1) 1.5 (0–2) 0 (0–2) 0 (0–2) 1 (0–2) 0.5 (0–1) 1 (0–2) 1 (0–2) 
Number of prior endocrine regimens, median (range)  
Any setting 3.5 (2–4) 3 (2–6) 2 (2–4) 3.5 (1–5) 3 (1–5) 2.5 (1–4) 3 (1–4) 3 (1–6) 
Prior treatment with an AI (total), n (%) 
Adjuvant setting 1 (25.0) 1 (16.7) 0 (0.0) 1 (16.7) 3 (25.0) 3 (50.0) 0 (0.0) 9 (20.0) 
Metastatic setting 4 (100.0) 6 (100.0) 5 (100.0) 5 (83.3) 12 (100.0) 3 (50.0) 6 (100.0) 41 (91.0) 
Prior treatment with 
fulvestrant, n (%) 
3 (75.0) 4 (66.7) 2 (40.0) 2 (33.3) 7 (58.3) 4 (66.7) 3 (50.0) 25 (55.6) 
Prior treatment with 
CDK4/6 inhibitors, n (%) 
0 (0.0) 0 (0.0) 0 (0.0) 2 (33.3) 4 (33.3) 1 (16.7) 0 (0.0) 7 (15.6) 
Prior treatment with 
mTOR inhibitors, n (%) 
2 (50.0) 3 (50.0) 0 (0.0) 3 (50.0) 6 (50.0) 2 (33.3) 2 (33.3) 18 (40.0) 
aPooled data from dose escalation and expansion groups. 248 
bVisceral disease includes patients with disease site at baseline of lung, liver (including biliary tract), hepatic, brain, pleural, 249 
and/or peritoneal involvement. 250 
AI=aromatase inhibitor; BID=twice daily; CDK=cyclin-dependent kinase; ECOG=Eastern Cooperative Oncology Group; 251 
mTOR=mechanistic target of rapamycin; QD=once daily. 252 
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Table 2. Causally relateda AEs occurring in more than three patients (≥5%) treated with AZD9496 253 
Causally related AEs by 
preferred term, n (%) 
20 mg QD 
n = 4 
40 mg BID 
n = 6 
80 mg BID 
n = 5 
150 mg BID 
n = 6 
250 mg BIDb 
n = 12 
400 mg BID 
n = 6 
600 mg BID 
n = 6 
Total 
n = 45 
Grade 1 Grade 2 Grade 3 All grades 
Diarrhea 0 2 (33.3) 2 (40.0) 0 5 (41.7) 4 (66.7) 3 (50.0) 10 (22.2) 3 (6.7) 3 (6.7) 16 (35.6) 
Fatigue 3 (75.0) 2 (33.3) 1 (20.0) 1 (16.7) 4 (33.3) 2 (33.3) 1 (16.7) 8 (17.8) 5 (11.1) 1 (2.2) 14 (31.1) 
Nausea 0 0 0 3 (50.0) 2 (16.7) 3 (50.0) 2 (33.3) 9 (20.0) 1 (2.2) 0 10 (22.2) 
Abdominal pain (upper) 0 1 (16.7) 1 (20.0) 1 (16.7) 1 (8.3) 0 2 (33.3) 6 (13.3) 0 0 6 (13.3) 
Hot flush 1 (25.0) 0 0 0 1 (8.3) 3 (50.0) 0 5 (11.1) 0 0 5 (11.1) 
ALT increased 0 0 0 0 1 (8.3) 2 (33.3) 1 (16.7) 1 (2.2) 1 (2.2) 2 (4.4) 4 (8.9) 
Vomiting 0 1 (16.7) 0 1 (16.7) 0 2 (33.3) 0 3 (6.7) 0 1 (2.2) 4 (8.9) 
AST increased 0 0 0 0 1 (8.3) 2 (33.3) 0 2 (4.4) 0 1 (2.2) 3 (6.7) 
Asthenia 0 0 0 0 2 (16.7) 0 1 (16.7) 3 (6.7) 0 0 3 (6.7) 
Flatulence 0 0 0 0 1 (8.3) 0 2 (33.3) 2 (4.4) 1 (2.2) 0 3 (6.7) 
Flushing 0 2 (33.3) 0 0 1 (8.3) 0 0 3 (6.7) 0 0 3 (6.7) 
Myalgia 0 1 (16.7) 1 (20.0) 1 (16.7) 0 0 0 3 (6.7) 0 0 3 (6.7) 
Vaginal discharge 0 0 0 1 (16.7) 1 (8.3) 1 (16.7) 0 3 (6.7) 0 0 3 (6.7) 
aCausally related to the study drug in the investigator’s opinion. 254 
bPooled data from dose escalation and expansion groups. 255 
AEs=adverse events; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BID=twice daily; CTCAE=Common Terminology Criteria for AEs; QD=once daily.256 
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Three patients experienced DLTs, which were reversible in all patients. One patient in the 150 mg 257 
BID cohort experienced abnormal hepatic functions (elevated aspartate aminotransferase [AST], 258 
alanine aminotransferase [ALT], gamma-glutamyl transferase [GGT] [grade 3], bilirubin, and alkaline 259 
phosphatase [ALP] [grade 2]). AZD9496 was withdrawn, and the abnormal hepatic functions 260 
returned to baseline. One patient in the 400 mg BID cohort experienced grade 3 diarrhea and grade 261 
3 elevated AST, ALT, and GGT, and was managed with dose interruption and reduction. A further 262 
patient, in the 600 mg BID cohort, experienced grade 3 diarrhea, which was managed with dose 263 
interruption. Dose escalation was stopped at 600 mg BID. All other causally related grade ≥3 events 264 
resolved, and no AEs leading to death were reported. 265 
Pharmacokinetics 266 
Single dose pharmacokinetics of AZD9496 267 
Following a single dose on Day 1, AZD9496 was rapidly absorbed at all dose levels, with median Tmax 268 
1.55–3.0 hours (Figure 1 Panel A; Table 3). Plasma concentrations underwent a rapid and biphasic 269 
decline following the peak, with a mean alpha half-life of 0.99–1.99 hours and a mean terminal 270 
half-life of 1.4–5.7 hours (Table 3).  271 
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Table 3. PK parameters for AZD9496 following single doses (Day 1) and multiple doses (Day 15) 272 
 
20 mg QD 
(N = 4) 
40 mg BID 
(N = 6) 
80 mg BID 
(N = 5) 
150 mg BID 
(N = 6) 
250 mg BIDa 
(N = 12) 
400 mg BID 
(N = 6) 
600 mg BID 
(N = 6) 
Day 1 
Cmax, ng/mL (gCV%) 
(n) 
260 (52) 
(n = 4) 
338 (73) 
(n = 4) 
536 (40) 
(n = 5) 
1,163 (95) 
(n = 5) 
2,779 (26) 
(n = 9) 
2,577 (53) 
(n = 6) 
7,313 (60) 
(n = 3) 
AUCinf, h·ng/mL (gCV%) 
(n) 
546 (56) 
(n = 4) 
1,046 (98) 
(n = 3) 
1,368 (22) 
(n = 3) 
4,550 (99) 
(n = 4) 
11,040 (19) 
(n = 5) 
11,580 (77) 
(n = 3) 
36,390 (69) 
(n = 3) 
tmax, h (min, max) 1.75 (1.50, 2.00) 
(n = 4) 
1.50 (1.00, 4.05) 
(n = 4) 
2.00 (1.50, 3.00) 
(n = 5) 
2.95 (1.50, 3.00) 
(n = 5) 
2.03 (1.55, 3.00) 
(n = 9) 
2.10 (1.12, 3.00) 
(n = 6) 
3.00 (2.00, 4.05) 
(n = 6) 
α-t½, h (SD) 
(n) 
0.92 (0.15) 
(n = 4) 
1.1 (0.17) 
(n = 4) 
1.2 (0.23) 
(n = 5) 
1.2 (0.25) 
(n = 5) 
1.3 (0.10) 
(n = 9) 
1.5 (0.36) 
(n = 6) 
1.9 (0.30) 
(n = 3) 
t½, h (SD) 
(n) 
1.37 (0.42) 
(n = 4) 
2.33 (1.94) 
(n = 3) 
1.79 (0.95) 
(n = 3) 
4.23 (1.28) 
(n = 4) 
5.72 (2.68) 
(n = 5) 
3.95 (0.74) 
(n = 3) 
2.30 (0.52) 
(n = 3) 
Day 15 
Cmax, ng/mL (gCV%) 
(n) 
200 (53) 
(n = 4) 
215 (62) 
(n = 6) 
385 (26) 
(n = 5) 
591 (44) 
(n = 6) 
1,478 (57) 
(n = 9) 
1,195 (65) 
(n = 5) 
2,758 (61) 
(n = 6) 
AUCtau, h·ng/mL (gCV%) 
(n) 
585 (156) 
(n = 4) 
637 (58) 
(n = 6) 
1,025 (31) 
(n = 5) 
1,664 (51) 
(n = 6) 
3,841 (67) 
(n = 9) 
3,642 (53) 
(n = 5) 
8,676 (50) 
(n = 6) 
tmax, h (min, max) 1.50 (1.42, 2.20) 
(n = 4) 
1.49 (0.95, 2.00) 
(n = 6) 
1.98 (1.17, 3.00) 
(n = 5) 
1.50 (1.00, 3.00) 
(n = 6) 
1.50 (1.00, 2.00) 
(n = 9) 
2.00 (1.00, 3.00) 
(n = 5) 
1.99 (1.50, 3.00) 
(n = 6) 
α-t½, h (SD) 
(n) 
1.1 (0.65) 
(n = 4) 
1.2 (0.55) 
(n = 6) 
3.3 (3.24) 
(n = 5) 
1.2 (0.31) 
(n = 6) 
1.0 (0.23) 
(n = 9) 
1.1 (0.23) 
(n = 5) 
1.1 (0.59) 
(n = 5) 
Temporal change for AUC 
(SD) 
1.35 (1.17) 
(n = 4) 
0.76 (0.21) 
(n = 3) 
0.65 (1.16) 
(n = 3) 
0.40 (0.16) 
(n = 4) 
0.43 (0.09) 
(n = 3) 
NC 0.23 (0.07)  
(n = 3) 
aPooled data from dose escalation and expansion groups. 273 
Temporal change for AUC calculated as follows: AUCtau/AUCinf. 274 
Data are geometric mean (gCV%) for Cmax and the AUC variables, arithmetic mean (SD) for α-t½, t½ and temporal change for AUC, and median (min, max) for tmax. 275 
α-t½=effective (alpha) half-life; t½=terminal elimination half-life; AUCinf=area under the concentration–time curve from zero to infinity; AUCtau=area under the concentration–time curve at 276 
steady-state over the dosing interval; BID=twice daily; Cmax=maximum plasma concentration; gCV=geometric coefficient of variation; EXP=expansion cohort; NC=not calculated (since n<3); 277 
QD=once daily; SD=standard deviation; tmax=time to observed Cmax. 278 
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Following a single AZD9496 dose of 20 mg up to 400 mg (Day 1), the area under the concentration–279 
time curve (AUC) increased in reasonable proportion to the increasing dose. At 600 mg, a more than 280 
dose-proportional increase in AUC and maximum concentration (Cmax) was observed. 281 
Multiple dose pharmacokinetics of AZD9496 282 
Multiple dose AUC and Cmax were consistently and dose-dependently lower than those for single 283 
dose for 40 mg up to 600mg. Based on the temporal change parameter (TCP) which compares AUCtau 284 
on Day 15 to AUCinf on Day 1, a time-dependent reduction in AZD9496 exposure was observed across 285 
the BID dose range, with more marked reductions at higher doses (mean reduction of 24% and 77% 286 
for the 40 mg BID and 600 mg BID dose level, respectively). No reduction in exposure was observed 287 
for the 20 mg QD dose group (Figure 1 Panel B, Table 3). These data correlated with the dose-288 
dependent increase in the marker for hepatic cytochrome P450 (CYP) induction (4β-hydroxy-289 
cholesterol:cholesterol ratio). The median (min, max) percentage change from baseline (Day 1) in 290 
4β-hydrox-ycholesterol:cholesterol ratio to Day 15 was between –5.7% (–16.4, 8.00) for the 20 mg 291 
QD dose and 247% (106, 298) for the 600 mg BID dose. 292 
Pharmacokinetics of metabolites 293 
Following single doses and at steady state, the plasma concentration–time profiles of metabolites 294 
M3 (around 30-fold lower in potency on ERα degradation than AZD9496) (20) and M5 (around 3-fold 295 
lower potency on ERα degradation than AZD9496) (20) closely followed that of AZD9496 but at 296 
lower concentrations (Figure S2; Table S1 and S2): around 9 to 20% was detected for M3 and around 297 
2% was detected for M5, relative to AZD9496 exposure. AZD9496 was not detected in urine. 298 
Preliminary anti-tumor efficacy 299 
Duration on treatment 300 
The median duration on treatment with AZD9496 was 2.1 months (range 0.7 to 21.1 months, across 301 
the range of doses examined). Twelve patients (26.6%) received AZD9496 for 6 months or longer, 302 
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and 10 patients (22.2%) and four patients (8.9%) exhibited stable disease at 6 and 12 months’ 303 
follow-up, respectively. Treatment was ongoing in six patients (13.3%) up to the data cut-off of 31 304 
January 2017 (Figure 2).  305 
Tumor responses 306 
One patient in the 250 mg BID cohort was observed to have had a partial response at Cycle 9 307 
(Day 251), which was confirmed by a subsequent scan 4 weeks later (Figure 3). This patient had 308 
metastatic breast cancer at study entry and had received eight prior chemotherapy regimens’ she 309 
was fulvestrant naïve, and had not received prior CDK 4/6 or mTOR inhibitor therapy (Figure 2). In 310 
this patient, the serum tumor marker Ca15.3 (raised at baseline: 60 U/mL) started to decrease early 311 
(2 months after starting AZD9496) and steadily, to reach normal levels after Cycle 8 (23 U/mL). This 312 
biochemical response was maintained at the time of RECIST partial response (15 U/mL) and at the 313 
last assessment before data cut-off, 2 months later (10 U/mL). 314 
Panels C and D: CT confirming RECIST partial response at Cycle 9. No change compared with previous scan performed 315 
4 weeks prior (05 October 2016). 316 
Discussion 317 
Resistance to endocrine therapies is an important clinical challenge, and continues to drive the 318 
search for more effective agents (1). Fulvestrant is effective in patients with metastatic breast 319 
cancer, including those who experience progression after endocrine treatment, but is associated 320 
with administration and PK limitations at its approved 500 mg once-monthly intramuscular dose. An 321 
orally bioavailable SERD, without the bioavailability and PK limitations of fulvestrant, is clearly an 322 
unmet medical need. 323 
This first in human study investigated the safety and tolerability of AZD9496: a new, non-steroidal 324 
small-molecule inhibitor of ERα, which has shown promise in preclinical models of ER+ advanced 325 
breast cancer (17). To our knowledge, this is the first published manuscript reporting results of a 326 
completed first in human study with an oral SERD. 327 
Research. 
on March 13, 2018. © 2018 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on February 13, 2018; DOI: 10.1158/1078-0432.CCR-17-3102 
 Page 19 of 23  
AZD9496 was shown to have a tolerable safety profile, with most AEs of CTCAE grade 1 or 2. 328 
The most common causally related AEs were diarrhea, fatigue, nausea, and upper abdominal pain, 329 
but these were largely mild (grade 1 or 2) and manageable without dose reduction or interruption. 330 
Two patients (4.4%) experienced a causally related SAE (diarrhea and abnormal hepatic function 331 
tests), and seven patients (15.6%) experienced a causally related grade 3 AE. DLTs were observed in 332 
three patients, and all were reversible. One patient (150 mg BID) experienced abnormal hepatic 333 
functions, another (400 mg BID) developed grade 3 diarrhea and abnormal hepatic functions, and 334 
another (600 mg BID) developed grade 3 diarrhea. However, only one of these patients (receiving 335 
150 mg BID) permanently discontinued AZD9496, following which the abnormal hepatic functions 336 
returned to baseline. The other two DLTs (in patients receiving 400 and 600 mg BID) were resolved 337 
with dose reduction and/or interruption, and the patients remained on-study. Because no two 338 
patients in any cohort experienced a DLT, the MTD was not reached, and 600 mg BID was the 339 
maximum dose explored. 600 mg BID was regarded as the MFD on the basis of the number of tablets 340 
required for each dose. These findings suggest that AZD9496 is well tolerated and has an acceptable 341 
safety profile in this population. 342 
The PK of AZD9496 was characterized by a rapid absorption and fast biphasic decline with a short 343 
alpha phase half-life. Based on the interim PK analysis of the first 20 mg QD dose group, the dosing 344 
regimen was switched from QD to BID to prolong target coverage. The single-dose AUC increased in 345 
reasonable proportion to the increasing dose, up to 400 mg. At 600 mg, a more than dose-346 
proportional increase in AUC and Cmax was observed. Following multiple dosing, AUC and Cmax were 347 
consistently and dose-dependently lower than for a single AZD9496 dose for 40 mg up to 600 mg. 348 
This was presumed to result from auto-induction of cytochrome P450 (CYP) isoenzymes (e.g. CYP3A), 349 
as suggested by in vitro studies and supported by the dose-dependent increase in the marker for 350 
hepatic CYP3A induction (4β-hydroxy-cholesterol:cholesterol ratio). It was assumed that steady-state 351 
conditions were reached at Day 15. The clinical relevance of this CYP induction with regards to co-352 
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medications and combinability with other cancer drugs is currently unknown and needs further 353 
investigation in future clinical studies.  354 
We obtained evidence of therapeutic activity in one patient at the 250 mg BID dose who had a 355 
confirmed partial response, and experienced a steady fall in levels of tumor marker Ca15.3. The 356 
steady-state exposure observed in patients at a dose of 250 mg BID was comparable to that in the 357 
pre-clinical patient-derived MCF-7 xenograft model in mice observed at a dose of 5 mg/kg AZD9496, 358 
which was the minimal dose required to see significant tumor growth inhibition in this model (21). 359 
Furthermore, ten patients (22.2%) were deemed to have stable disease at 6 months or longer 360 
follow-up. Based on the clinical activity and the safety and tolerability profile of AZD9496 at the 250 361 
mg BID dose, this was selected as the recommended dose for the subsequent AZD9496 study. Paired 362 
evaluable tumor biopsies were obtained from five of the 45 patients in the study highlighting the 363 
challenges in conclusively assessing proof-of-mechanism in tumor tissue in Phase 1 studies. The 364 
pharmacodynamic biopsy data will be presented separately (manuscript in preparation).  365 
We note some limitations to this study. Firstly, cohorts were small, containing between four and six 366 
patients only, and this may have been insufficient to detect the less frequent effects of AZD9496 367 
treatment. Secondly, the minimum washout period between previous anti-cancer regimens and 368 
starting AZD9496 treatment was 14 days. Since fulvestrant has a half-life of 50 days, the possibility 369 
that these results include synergistic effects of AZD9496 and fulvestrant cannot be ruled out. Thirdly, 370 
this study was a non-randomized, non-comparator trial, so assessment of both efficacy and safety 371 
may be difficult in this heavily pre-treated, heterogeneous population.   372 
This Phase 1 study suggests that AZD9496 has an acceptable safety and tolerability profile, and 373 
shows preliminary evidence of prolonged stabilization of disease in some women with heavily 374 
pre-treated, advanced breast cancer, including in those previously treated with fulvestrant. 375 
A pre-surgical window of opportunity study (NCT03236974) will now compare the pharmacodynamic 376 
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effects of AZD9496 (expression of ER, PR, and Ki67 in tumor tissue) with those of fulvestrant in 377 
women with hormone receptor positive early breast cancer awaiting surgery with curative intent. 378 
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CCR-17-3102R1: Figure titles and legends  
Figure 1 Title: 
AZD9496 geometric mean plasma concentration–time profiles following a single dose or 
multiple doses (n = 3–5 subjects) 
Figure 1 Legend:  
Panel A: AZD9496 geometric mean plasma concentration following a single dose of AZD9496 
on Day 1 (semi-log scale). Panel B: Geometric mean plasma concentration following multiple 
doses of AZD9496 on Day 15 (semi-log scale). On Day 15 at all doses except 20 mg, the 24 h 
time point is the 12 h trough concentration following the evening dose of AZD9496 and 
therefore not shown. 
aPooled data from dose escalation and expansion groups. 
 
BID=twice daily; QD=once daily; EXP=expansion cohort. 
Figure 2 Title:  
Duration on AZD9496 treatment by dose (cohort) and prior fulvestrant 
Figure 2 Legend:  
Data cut off: 31 January 2017. Patients are ordered on the y-axis by cohort. When a patient 
received fulvestrant in several lines, the duration of most the most recently received is 
shown. 
 
BID=twice daily; EXP=dose expansion group; PR=partial response; QD=once daily. 
Figure 3 Title:  
CT scans showing confirmed partial response in one patient (250 mg BID). 
Figure 3 Legend: 
Panels A and B: Baseline staging CT. Right pleural nodules with further nodules extending in 
the right pericardiophrenic fat. Multiple nodules extending along the right oblique and 
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